URO-1, Inc. is a life sciences company dedicated to advancing the tools and workflows used in soft tissue biopsy diagnostics.
Prostate cancer stands as a prevalent threat to men's health, ranking second in cancer-related deaths in the United States. Each year, approximately 250,000 men in the U.S. receive a prostate cancer ...
Morning Overview on MSN
Study finds microplastics in 90% of prostate cancer tumors
Researchers at NYU Langone Health have detected tiny plastic fragments in nine out of 10 prostate cancer tumors examined, a ...
Benefits include better discrimination between risk levels. (HealthDay News) — Patient-centered pathology reports (PCPR) help patients to understand prostate cancer results better than current ...
Individual patient data (IPD) analysis of early PSA nadir in ARASENS, LATITUDE, and TITAN: Training and validation of a novel model. Assessing genomic instability (GI) by shallow whole-genome ...
The Prostate Cancer Foundation (PCF) today announced the recipients of its 2025 Challenge Awards, providing over $12 million in funding for 12 multi-institutional, cross-disciplinary research teams ...
There is ongoing clinical need to improve estimates of disease outcome in prostate cancer. Machine learning (ML) approaches to pathologic diagnosis and prognosis are a promising and increasingly used ...
Human tissue is intricate, complex and, of course, three dimensional. But the thin slices of tissue that pathologists most often use to diagnose disease are two dimensional, offering only a limited ...
If you’ve recently been diagnosed with prostate cancer, or if you’ve had a prostate biopsy to test for prostate cancer, you might have seen the term “Gleason score” or “Gleason grade” on the pathology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results